The announcement was made at Biomarkers UK, and it was used as an opportunity to showcase Metabolon’s latest platform designed, the company says, to propel the landscape of metabolomics analysis.
Drawing on more than two decades of industry-leading experience, Metabolon says it now boasts an established database of more than 5,400 biologically relevant metabolites, the platform seamlessly integrates a comprehensive suite of tools and features.
Among these features is pathway analysis, enabling researchers to explore the intricate workings of biological processes and uncover insights into disease mechanisms and therapeutic targets.
Biomarker Lenses, a feature unique to Metabolon, provides advanced analytical filters to enhance the exploration of metabolomic data by focusing on specific pathways and diseases.
Interpretation of complex data sets
Principle Component Analysis (PCA) aids researchers in reducing complex datasets and visualizing research results effectively. Partial Least Squares–Discriminant Analysis (PLS-DA) facilitates the interpretation of complex datasets, allowing for the identification of distinctive biomarkers driving group separation.
Researchers can now organize metabolites and samples into meaningful groups based on metabolite features using the clustering feature of the database, the company said. Another feature volcano plots assist in identifying statistically significant changes in large datasets, revealing biologically relevant metabolites.
David Broadhurst, professor of biosystems data science at Edith Cowan University, Australia, said: “I love working with Metabolon data. It is an incredibly forward-thinking company, actively engaging with the evolving interdisciplinary challenges of robust clinical metabolomics.
“Metabolon has developed a solid, scalable solution to the non-trivial problem of metabolomics biochemical interpretation, specifically tailored to their world-leading data acquisition platform. Leveraging decades of experience in data curation, Metabolon provides intuitive visualization tools for pathway analysis and disease association, adding even more value to an already outstanding product.”
Alleviating the manual burden of data organization
The company says that in an era where precision medicine, advanced analytics, and big data reign supreme, its platform alleviates the manual burden of data organization and preparation. The platform pre-populates client data, expediting discovery with publication-ready charts, plots, data tables, and insights.
Ray Moran, senior director of bioinformatics at Metabolon, said: Metabolon is thrilled to unveil this groundbreaking bioinformatics platform, marking a significant leap forward in metabolomics research.
“By combining our extensive industry experience with cutting-edge technology, we are empowering researchers to navigate complex data effortlessly and accelerate discoveries in the life sciences.”
